Literature DB >> 21505542

Fine needle diathermy - a choice for managing corneal vascularization.

S Thatte1.   

Abstract

INTRODUCTION: Corneal vascularization develops as a result of various corneal diseases. Fine- needle diathermy (FND) is one of the methods to occlude corneal vessels.
OBJECTIVE: To evaluate the efficacy and safety of this method in a series of patients with corneal vascularization.
MATERIALS AND METHODS: Twenty eight patients with corneal vascularization were treated with FND. The patients were divided into four groups according to etiological factors like pre-keratoplasty (high risk patients), increased keratopathy, recurrent inflammation and postkeratoplasty rejection .The FND was performed under local anaesthesia with the help of a corneal needle of 10-0 monofilament nylon suture. The success of treatment was evaluated in terms of regression and occlusion of corneal vessels.
RESULTS: The main aim of a complete occlusion of blood vessels was achieved in all patients. The most frequent complication seen was a transient whitening of the cornea especially around the needle entry in nine cases, which cleared within 24 hours.
CONCLUSION: FND is a simple safe, inexpensive and effective treatment. It can be repeated and used as an alternative therapy for corneal vascularization. © NEPjOPH.

Entities:  

Mesh:

Year:  2011        PMID: 21505542     DOI: 10.3126/nepjoph.v3i1.4274

Source DB:  PubMed          Journal:  Nepal J Ophthalmol        ISSN: 2072-6805


  2 in total

Review 1.  Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).

Authors:  William Stevenson; Sheng-Fu Cheng; Mohammad H Dastjerdi; Giulio Ferrari; Reza Dana
Journal:  Ocul Surf       Date:  2012-01-25       Impact factor: 5.033

2.  Fine Needle-Diathermy Regresses Pathological Corneal (Lymph)Angiogenesis and Promotes High-Risk Corneal Transplant Survival.

Authors:  Viet Nhat Hung Le; Ann-Charlott Schneider; Rebecca Scholz; Felix Bock; Claus Cursiefen
Journal:  Sci Rep       Date:  2018-04-09       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.